Cancer-related Venous Thromboembolic Disease - Cohort Study
Establishment of a Patient-based Cohort : Cancer-related Venous Thromboembolic Disease.
University Hospital, Brest
150 participants
Oct 30, 2025
OBSERVATIONAL
Conditions
Summary
Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.
Eligibility
Inclusion Criteria5
- Patients aged 18 years and more.
- Patients with active cancer or requiring cancer treatment at the time of their VTE episode
- Patients with documented VTE less than 2 years old
- Patients affiliated to the social security system
- Patient who has signed a written informed consent
Exclusion Criteria6
- Patient under 18
- Refusal to participate
- Incapacity to consent to the study
- Patient under guardianship
- Incapacity to communicate (comprehension disorder)
- Life expectancy of less than 6 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Collecte of blood and urine samples
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06393764